根据PAM50内在亚型评估CDK4/6抑制剂联合内分泌治疗激素受体阳性/HER2阴性晚期乳腺癌的疗效结局:SOLTI-1801 CDK-PREDICT研究主要结果
CDK-PREDICT是一项在六家西班牙医院开展的多中心、双向性观察性队列研究,纳入185例一线接受CDK4/6抑制剂联合内分泌治疗的HR+/HER2-晚期乳腺癌患者,中位随访38.5个月。非管腔型亚型的中位无进展生存期(10.2 vs. 25.7个月;HR 2.50;p<0.001)和总生存期(32.3 vs. 58.1个月;HR 2.54;p<0.001)均显著短于管腔型亚型。研究确认PAM50内在亚型具有独立预后价值,非管腔型预后最差,提示该人群需要新的治疗策略。
要点
- 非管腔型中位PFS 10.2个月 vs 管腔型25.7个月(HR 2.50;p<0.001)。
- 非管腔型中位OS 32.3个月 vs 管腔型58.1个月(HR 2.54;p<0.001)。
- CCNE1、PDCD1等高表达及肿瘤浸润淋巴细胞与更差结局相关。
核心结论
- 本研究确认PAM50内在亚型在CDK4/6抑制剂联合内分泌治疗一线治疗的HR+/HER2-晚期乳腺癌中具有独立预后价值。
- 非管腔型亚型预后最差,提示该人群需要新的治疗策略。
研究设计与样本
- CDK-PREDICT研究为在六家西班牙医院开展的多中心、双向性观察性队列研究。
- 纳入185例一线接受CDK4/6抑制剂联合内分泌治疗的HR+/HER2-晚期乳腺癌患者,中位随访38.5个月。
- 治疗前获取基线活检,检测研究用PAM50内在亚型、细胞周期及免疫相关基因表达。
- 主要目标为采用单因素和多因素Cox回归模型评估PAM50内在亚型间的无进展生存期差异。
- 次要目标包括总生存期、总缓解率,以及细胞周期和免疫反应基因表达与PFS的相关性。
主要发现
- PAM50管腔型亚型占82.7%。
- 非管腔型亚型中位PFS为10.2个月 vs 管腔型25.7个月(HR 2.50;p<0.001)。
- 非管腔型亚型中位OS为32.3个月 vs 管腔型58.1个月(HR 2.54;p<0.001)。
- CCNE1、PDCD1等细胞周期和免疫相关基因高表达及肿瘤浸润淋巴细胞与更差结局相关。
临床怎么用
- 原文结论指出非管腔型亚型预后最差,凸显该人群需要新的治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The prognostic value of PAM50 intrinsic subtypes (IS), cell cycle, and immune-related gene expression in HR+ /HER2- advanced breast cancer (BC) treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) in a first-line metastatic setting is unclear. This study evaluates these biomarkers in metastatic biopsies from patients diagnosed with HR+ /HER2- advanced BC. METHODS: CDK-PREDICT study is a multicentric, ambispective observational cohort study conducted in six Spanish hospitals. It included patients diagnosed with HR+ /HER2- advanced BC treated in the first-line setting with CDK4/6i and ET. Baseline biopsies were obtained prior to treatment to determine research-based PAM50 IS, cell cycle and immune-related gene expression. The primary objective was to evaluate progression-free survival (PFS) differences among PAM50 IS using uni- and multivariable Cox regression models. Secondary objectives included overall survival (OS), overall response rate (ORR), and correlating cell cycle and immune response gene expression with PFS. RESULTS: A total of 185 patients were included, with a median follow-up of 38.5 months. PAM50 luminal subtypes were predominant (82.7 %). Non-luminal subtypes showed significantly shorter median PFS (10.2 vs. 25.7 months; HR, 2.50; p < 0.001) and OS (32.3 vs. 58.1 months; HR, 2.54; p < 0.001) than luminal subtypes. Higher cell cycle and immune-related genes expression, such as CCNE1 and PDCD1, as well as tumor infiltrating lymphocytes were associated with poorer outcomes. CONCLUSIONS: This study confirms the independent prognostic value of PAM50 IS in HR+ /HER2- advanced BC treated with CDK4/6i and ET. Non-luminal subtypes exhibited the worst prognosis, underscoring the need for novel therapeutic strategies in this population.
引用
- Tolosa P, Pascual T, Martínez-Saez O, et al. Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study. Eur J Cancer. 2025. PMID: 39779447. doi:10.1016/j.ejca.2024.115219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。